共 216 条
[1]
Fukuchi Y(2020)Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet Respir Med 8 585-596
[2]
Nishimura M(2004)COPD in Japan: the Nippon COPD epidemiology study Respirology 9 458-465
[3]
Ichinose M(2017)Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary Respirology 22 575-601
[4]
Adachi M(2020)Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society Clinical Practice Guideline Am J Respir Crit Care Med 201 e56-e69
[5]
Nagai A(2017)Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline Eur Respir J 50 1602265-1196
[6]
Kuriyama T(2016)A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD Chest 149 1181-71
[7]
Vogelmeier CF(2019)The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects Ther Adv Respir Dis 13 1753466619843426-979
[8]
Criner GJ(2018)Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA Respir Med 139 65-344
[9]
Martinez FJ(2015)Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) Eur Respir J 45 969-1419
[10]
Anzueto A(2018)Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial Lancet Respir Med 6 337-2156